Section
Pipeline
Late-stage drugs with significant commercial implications
PipelineFiercePharma ↗
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ s…
PipelineFierceBiotech ↗
An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's proposal of using its oral SERD camizestran…
PipelineBriefing
FDA authorizes Auvelity for agitation tied to Alzheimer’s disease, positioning Axsome’s NMDA/sigma-1 modulator…
PipelineBioPharma Dive ↗
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still…
PipelineFiercePharma ↗
The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and…
PipelineEndpoints News ↗
Bristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer,…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.